Cas 220615-33-8,(+/-)-1-(3-((4'-cyano-(1,1'-biphenyl)-4-yl)oxy)-propan-2-on-1-yl)-3,4,4-trimethyl-2,5-dioxoimidazolidine

220615-33-8

Post Buying Request

Basic information

Product Name: (+/-)-1-(3-((4'-cyano-(1,1'-biphenyl)-4-yl)oxy)-propan-2-on-1-yl)-3,4,4-trimethyl-2,5-dioxoimidazolidine
Synonyms: (+/-)-1-(3-((4'-cyano-(1,1'-biphenyl)-4-yl)oxy)-propan-2-on-1-yl)-3,4,4-trimethyl-2,5-dioxoimidazolidine
CAS NO:220615-33-8
Molecular Formula:
Molecular Weight: 391.426
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: (+/-)-1-(3-((4'-cyano-(1,1'-biphenyl)-4-yl)oxy)-propan-2-on-1-yl)-3,4,4-trimethyl-2,5-dioxoimidazolidine(CAS DataBase Reference)
NIST Chemistry Reference: (+/-)-1-(3-((4'-cyano-(1,1'-biphenyl)-4-yl)oxy)-propan-2-on-1-yl)-3,4,4-trimethyl-2,5-dioxoimidazolidine(220615-33-8)
EPA Substance Registry System: (+/-)-1-(3-((4'-cyano-(1,1'-biphenyl)-4-yl)oxy)-propan-2-on-1-yl)-3,4,4-trimethyl-2,5-dioxoimidazolidine(220615-33-8)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 220615-33-8(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

220615-33-8 Suppliers

Recommended suppliers

220615-33-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 220615-33-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,0,6,1 and 5 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 220615-33:
(8*2)+(7*2)+(6*0)+(5*6)+(4*1)+(3*5)+(2*3)+(1*3)=88
88 % 10 = 8
So 220615-33-8 is a valid CAS Registry Number.

220615-33-8Upstream product

220615-33-8Downstream Products

220615-34-9 4'-[2-hydroxyamino-3-(3,4,4-trimethyl-2,5-dioxo-imidazolidin-1-yl)-propoxy]-biphenyl-4-carbonitrile

220615-33-8Relevant academic research and scientific papers

N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES

-

, (2008/06/13)

Compounds having formula (I) are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors

Michaelides, Michael R.,Dellaria, Joseph F.,Gong, Jane,Holms, James H.,Bouska, Jennifer J.,Stacey, Jamie,Wada, Carol K.,Heyman,Curtin, Michael L.,Guo, Yan,Goodfellow, Carole L.,Elmore, Ildiko B.,Albert, Daniel H.,Magoc, Terrance J.,Marcotte, Patrick A.,Morgan, Douglas W.,Davidsen, Steven K.

, p. 1553 - 1556 (2007/10/03)

A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%).

REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES

-

, (2008/06/13)

Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

Reverse hydroxamate inhibitors of matrix metalloproteinases

-

, (2008/06/13)

Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770

Curtin, Michael L.,Florjancic, Alan S.,Heyman,Michaelides, Michael R.,Garland, Robert B.,Holms, James H.,Steinman, Douglas H.,Dellaria, Joseph F.,Gong, Jane,Wada, Carol K.,Guo, Yan,Elmore, Ildiko B.,Tapang, Paul,Albert, Daniel H.,Magoc, Terrance J.,Marcotte, Patrick A.,Bouska, Jennifer J.,Goodfellow, Carole L.,Bauch, Joy L.,Marsh, Kennan C.,Morgan, Douglas W.,Davidsen, Steven K.

, p. 1557 - 1560 (2007/10/03)

Modification of the biphenyl portion of MMP inhibitor 2a gave analogue 2i which is greater than 1000-fold selective against MMP-2 versus MMP-1. The stereospecific synthesis of both enantiomers of 2i was achieved beginning with (S)- or (R)-benzyl glycidyl ether. The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth. Elsevier Science Ltd. All rights reserved.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 220615-33-8